Abstract
In this study we show that cytarabine given simultaneously with 5-aza-2'-deoxycytidine (Aza-dC) antagonized Aza-dC activity against L1210 mouse leukemia. This antagonism was seen after a single dose (on Day 3 or Day 5 after tumor implant) and after repeated doses. This observation suggests caution in combining cytarabine with Aza-dC in the treatment of human leukemias.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Azacitidine / administration & dosage
-
Azacitidine / analogs & derivatives*
-
Azacitidine / antagonists & inhibitors
-
Cytarabine / administration & dosage
-
Decitabine
-
Drug Interactions
-
Leukemia L1210 / drug therapy*
-
Leukemia L1210 / pathology
-
Male
-
Mice
-
Statistics as Topic
Substances
-
Cytarabine
-
Decitabine
-
Azacitidine